Redhill Biopharma Ltd
RDHL
Company Profile
Business description
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
Contact
21 Ha’arba’a Street
Tel Aviv6473921
ISRT: +972 35413131
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
35
Stocks News & Analysis
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
stocks
Magellan Financial Group: A dilutive acquisition of Barrenjoey
Our view of the proposed merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,326.10 | 74.60 | -0.79% |
| CAC 40 | 8,394.32 | 186.43 | -2.17% |
| DAX 40 | 24,638.00 | 646.26 | -2.56% |
| Dow JONES (US) | 48,838.69 | 139.23 | -0.28% |
| FTSE 100 | 10,780.11 | 130.44 | -1.20% |
| HKSE | 26,127.36 | 67.51 | 0.26% |
| NASDAQ | 22,706.85 | 38.64 | 0.17% |
| Nikkei 225 | 57,369.87 | 687.37 | -1.18% |
| NZX 50 Index | 13,629.47 | 93.50 | -0.68% |
| S&P 500 | 6,875.63 | 3.25 | -0.05% |
| S&P/ASX 200 | 9,102.90 | 65.20 | -0.71% |
| SSE Composite Index | 4,193.66 | 11.07 | 0.26% |